|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
|
| Published Date:
October 2009
Published By:
Datamonitor
Page Count:
256
Order Code:
R313-55067
|
|
|
|
Introduction
Drugs with new mechanisms, in particular Pfizer’s oral JAK inhibitor CP-690,550 and Chugai/Roche’s Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals. Late-stage pipeline launches will be a major contributor to market growth from $7.4 billion in 2008 to $11.5 billion in 2018.
Scope- In-depth analysis of Phase II and III disease modifying drug candidates in the rheumatoid arthritis pipeline
- Segmentation and analysis of the current rheumatoid arthritis pipeline by developmental phase, drug class and company
- Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
- Focus on innovative early-stage drug development with assessment of future treatment of rheumatoid arthritis
Highlights
The shift from Western regions to countries in Eastern Europe and South America is now a prominent feature of modern rheumatoid arthritis clinical trials. This has led to variability in placebo and drug responses resulting in higher failure rates. This will continue to be a difficult hurdle for drug development in rheumatoid arthritis.
Pfizer’s JAK inhibitor CP-690,550 blazes the trail for small molecule kinase inhibitors in rheumatoid arthritis. Despite efficacy being in line with biologics, product positioning, safety and cost are key debatable issues for uptake of this new drug upon launch in 2012. Datamonitor forecasts sales in the seven major markets of $0.9 billion in 2018.
Pre-launch awareness, robust clinical data and marketing capability leads Datamonitor to believe Actemra (tocilizumab; Roche/Chugai) will have a significant impact on the market. Safety remains a question, but physicians are willing to deal with issues highlighted in clinical trials. Datamonitor expects Actemra to achieve blockbuster sales by 2015.
Reasons to Purchase- Understand the major recent advances in the dynamic and constantly evolving rheumatoid arthritis pipeline
- Evaluate the sales forecasts of key late-stage pipeline products to 2018 and understand new product positioning in this competitive market
- Assess key opinion leaders’ views on the most advanced pipeline products including Pfizer’s JAK inhibitor CP-690,550
Please note: this is delivered as a Zip file.
|
Similar Products
• Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC
• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
• Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
|
|
|
|
0 items
